|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
gptkb:phenothiazine_derivative
|
|
gptkbp:ATCCode
|
N05AA02
|
|
gptkbp:brand
|
gptkb:Levoprome
gptkb:Nozinan
|
|
gptkbp:CASNumber
|
60-92-4
|
|
gptkbp:chemicalFormula
|
C19H24N2OS
|
|
gptkbp:contraindication
|
coma
bone marrow depression
CNS depression
hypersensitivity to phenothiazines
|
|
gptkbp:developedBy
|
gptkb:France
|
|
gptkbp:discoveredBy
|
gptkb:Paul_Charpentier
|
|
gptkbp:drugClass
|
typical antipsychotic
|
|
gptkbp:eliminationHalfLife
|
15-30 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1950s
|
|
gptkbp:mechanismOfAction
|
gptkb:dopamine_receptor_antagonist
gptkb:histamine_receptor_antagonist
muscarinic receptor antagonist
alpha-adrenergic receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
328.47 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
|
|
gptkbp:PubChem_CID
|
4058
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
weight gain
QT prolongation
hypotension
sedation
extrapyramidal symptoms
anticholinergic effects
|
|
gptkbp:synonym
|
gptkb:Nozinan
gptkb:methotrimeprazine
levoprome
|
|
gptkbp:UNII
|
U0D3YWU464
|
|
gptkbp:usedFor
|
nausea
schizophrenia
vomiting
pain management
palliative care
psychosis
agitation
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Levomepromazine
|